Trials / Active Not Recruiting
Active Not RecruitingNCT03340376
Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer
Prospective Randomized Phase II Trial Comparing Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Academic / Other
- Sex
- Female
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, randomized phase II trial to evaluate the safety and efficacy of atezolizumab in patients with recurrent cervical cancer in second line therapy. A total of 48 patients will be randomized in 3 arms, each arm consisting of 16 patients: Arm A: atezolizumab monotherapy q3w Arm B: atezolizumab combined with doxorubicin q3w Arm C: doxorubicin monotherapy q3w
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | atezolizumab |
| DRUG | Doxorubicin | Doxorubicin |
Timeline
- Start date
- 2017-08-30
- Primary completion
- 2025-09-01
- Completion
- 2025-09-01
- First posted
- 2017-11-13
- Last updated
- 2024-07-03
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03340376. Inclusion in this directory is not an endorsement.